Novel antibody drug conjugates (ADCs) for improving outcomes for cancer patients

Neok Bio focuses on advancing biopharmaceuticals through its innovative platform that leverages synthetic biology and advanced protein engineering. The company is dedicated to developing next-generation therapeutics, particularly in the fields of immunology and oncology. By utilizing cutting-edge techniques, Neok Bio aims to create more effective and targeted treatments that can address unmet medical needs, enhancing patient outcomes and improving the overall efficacy of therapies.

The company's technology is centered around its proprietary methodologies that enable the design and optimization of biologics. This includes the development of novel antibodies and other protein-based therapeutics that can be tailored to specific disease targets. Neok Bio's approach emphasizes a deep understanding of biological systems, allowing for the creation of therapeutics that not only demonstrate improved performance but also possess enhanced safety profiles. Through its rigorous scientific research and commitment to innovation, Neok Bio is positioned to make significant contributions to the biopharmaceutical landscape.

United States

NEOK Bio, Inc. is a biotechnology company focused on the development of novel antibody drug conjugates (ADCs) that are designed to improve outcomes for cancer patients. NEOK is rapidly advancing bispecific ADCs which represent a cutting-edge advancement, leveraging bispecific antibodies that target two complimentary antigens, potentially improving safety while enhancing the efficacy of ADCs in a wider range of tumors. Backed by ABL Bio, Inc., a proven leader in antibody engineering, NEOK plans to initiate clinical studies for its two lead bispecific ADC candidates in solid tumor indications in mid-2026. 

Neok Bio

Company Details